Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPC vs GP induction chemotherapy plus concurrent chemoradiotherapy for high-risk locoregionally advanced nasopharyngeal carcinoma
ChiCTR2200061378Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel, cisplatin, paclitaxel and gemcitabine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
docetaxelcisplatinpaclitaxelgemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200061378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061378.